-
1
Vorinostat does not improve outcome in patients with acute myeloid leukemia and high risk myelodysplasia treated with azacitidine: Results of the UK Trials Acceleration Programme R...
Published 2016“…American Society of Hematology…”
Conference item -
2
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
Published 2023“…American Society of Hematology…”
Journal article -
3
Molecular MRD status and outcome after transplantation in NPM1-mutated AML
Published 2020“…American Society of Hematology…”
Journal article -
4
Therapy-Related Myeloid Neoplasms with Balanced Chromosome Rearrangements Frequently Arise from Pre-Existing Clonal Haematopoiesis
Published 2018“…American Society of Hematology…”
Conference item -
5
Results of a phase 2 trial of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukemia (CMML) - the UK monocle study
Published 2018“…American Society of Hematology…”
Conference item